Who makes V-306 candidate vaccine?

V-306 candidate vaccine is developed by Virometix.

What development phase is V-306 candidate vaccine in?

V-306 candidate vaccine is in Phase 1.

Last reviewed 2026-05-13 · How we verify

V-306 candidate vaccine

Virometix · Phase 1 active Biologic

At a glance

Generic name	V-306 candidate vaccine
Sponsor	Virometix
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Vaccine Against Respiratory Syncytial Virus (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

V-306 candidate vaccine CI brief — competitive landscape report
V-306 candidate vaccine updates RSS · CI watch RSS
Virometix portfolio CI